Research Analysts Offer Predictions for SABS Q1 Earnings

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for shares of SAB Biotherapeutics in a research note issued to investors on Wednesday, January 29th. HC Wainwright analyst E. White forecasts that the company will earn ($1.35) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q2 2025 earnings at ($1.32) EPS, Q3 2025 earnings at ($1.31) EPS, Q4 2025 earnings at ($1.34) EPS, FY2025 earnings at ($5.31) EPS and FY2026 earnings at ($4.03) EPS.

A number of other equities research analysts have also recently weighed in on SABS. Craig Hallum started coverage on shares of SAB Biotherapeutics in a research note on Wednesday, October 9th. They set a “buy” rating and a $11.00 price objective on the stock. Chardan Capital restated a “buy” rating and set a $25.00 price target on shares of SAB Biotherapeutics in a research report on Wednesday. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $12.40.

SAB Biotherapeutics Trading Up 0.9 %

Shares of SAB Biotherapeutics stock opened at $2.19 on Friday. SAB Biotherapeutics has a 1-year low of $2.00 and a 1-year high of $6.30. The business’s fifty day moving average price is $3.57 and its two-hundred day moving average price is $3.11. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%.

Hedge Funds Weigh In On SAB Biotherapeutics

A hedge fund recently bought a new stake in SAB Biotherapeutics stock. Kovitz Investment Group Partners LLC purchased a new position in SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 19,201 shares of the company’s stock, valued at approximately $52,000. Kovitz Investment Group Partners LLC owned about 0.21% of SAB Biotherapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.